(Q35145905)

6 August 2017

1 reference

title

A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy (English)

1 reference

6 August 2017

1 reference

Osamu Ohmori

1

1 reference

6 August 2017

Takahiro Shinkai

2

1 reference

6 August 2017

Hiroko Hori

3

1 reference

6 August 2017

Chima Matsumoto

4

1 reference

6 August 2017

Jun Nakamura

5

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

6 August 2017

published in

1 reference

6 August 2017

volume

27

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

581-586

1 reference

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Pharmacogenetic prediction of clozapine response

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Human Leucocyte Antigens and Tardive Dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Immunogenetic markers in chlorpromazine-induced tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Association between a polymorphism in the promoter region of the dopamine D2 receptor gene and schizophrenia in Japanese subjects: replication and evaluation for antipsychotic-related features.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Schizophrenia, tardive dyskinesia, and a D3 receptor gene variant: a new twist on dyskinesias?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Apolipoprotein E epsilon4 and tardive dyskinesia in a Japanese population

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Genetic predictors of therapeutic response to clozapine: current status of research

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

HLA antigens in tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Polymorphisms of mu and delta opioid receptor genes and tardive dyskinesia in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Pharmacogenomics of psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Dopamine D3 receptor variant and tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Angiotensin converting enzyme gene insertion/deletion polymorphism: case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900082-4

7 January 2021

10.1016/S0278-5846(03)00082-4

Identifiers

DOI

1 reference

6 August 2017

1 reference